Table 3

Responsiveness of individual items and indices, ranked by t value in the etanercept trial

	Active drug					Placebo					t Value
	Baseline	Mean Δ	SE_Δ	SRM	ES	Baseline	Mean Δ	SE_Δ	SRM	ES	t Value
CRP, C reactive protein; DAS, Disease Activity Score; ES, effect size; ESR, erythrocyte sedimentation rate; GST, global statistical test; HAQ, Health Assessment Questionnaire; IMPACT, Infliximab Multinational Psoriatic Arthritis Controlled Trial; Mean Δ, mean change; MS, morning stiffness; PASI, Psoriasis Area and Severity Index; PhGA, physician global assessment; PtGA, patient global assessment; RAI, Ritchie Articular Index; SE_Δ, standard error of mean change; SJC, swollen joint count; SRM, standardised response mean; TJC, tender joint count.
DAS28 (0–10)	5.2	−2.0	0.2	−2.22	−1.51	4.7	0.2	0.2	0.14	0.12	8.6
GST	–	190	9.2	3.76	–	–	91	8.3	2.10	–	7.9
DAS (0–10)	3.9	−1.7	0.2	−1.74	−1.55	3.9	−0.0	0.2	−0.01	−0.01	7.4
PhGA (0–5)	3.3	−2.1	0.2	−1.98	−2.84	3.4	−0.3	0.2	−0.34	−0.32	7.0
TJC78 (0–78)	22.7	−14.2	2.0	−1.32	−1.17	25.3	4.2	1.9	0.42	0.22	6.6
TJC68 (0–68)	19.8	−12.1	1.8	−1.25	−1.19	20.5	5.6	2.0	0.53	0.42	6.6
PtGA (0–5)	3.3	−2.0	0.2	−1.51	−1.99	2.9	−0.1	0.8	−0.18	−0.18	6.4
TJC28 (0–28)	7.7	−5.3	0.8	−1.17	−1.08	7.2	2.9	1.2	0.48	0.59	5.8
SJC66 (0–66)	14.2	−9.4	1.15	−1.53	−1.16	15.4	−1.1	1.0	−0.20	−0.10	5.4
MS (min)	56.5	−35.8	5.4	−1.21	−1.61	59.7	1.3	5	0.05	0.09	5.0
HAQ (0–3)	1.23	−0.73	0.10	−1.32	−1.28	1.18	−0.07	0.09	−0.16	−0.13	4.8
SJC44 (0–44)	10.6	−6.5	0.9	−1.35	−1.01	11.6	−0.9	4.0	−0.22	−0.11	4.7
RAI (0–75)	12.7	−8.0	1.3	−1.18	−1.13	14.7	0.8	1.4	0.10	0.08	4.6
SJC76 (0–76)	15.7	−10.6	1.3	−1.49	−1.13	18.3	−2.5	1.3	−0.37	−0.18	4.4
SJC28 (0–28)	6.8	−3.9	0.6	−1.27	−0.84	6.2	−0.7	0.5	−0.25	−0.15	4.1
CRP (mg/l)	22.5	−15.0	3.2	−0.86	−0.70	16.3	2.1	3.0	0.13	0.15	3.8
Pain (0–5)	2.9	−1.8	0.2	−1.36	−1.45	3.1	−0.1	0.2	−0.07	−0.07	3.7
ESR (mm/h)	26.6	−15.2	3.1	−0.91	−0.58	23.2	−0.7	3.2	−0.05	−0.03	3.2
PASI (0–72)	12.7	−5.0	1.3	−0.89	−0.62	7.8	−0.4	1.2	−0.08	−0.08	2.6